366,028 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Hhlr Advisors LTD.

Hhlr Advisors LTD. bought a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 366,028 shares of the company’s stock, valued at approximately $10,922,000. Maze Therapeutics accounts for approximately 1.3% of Hhlr Advisors LTD.’s holdings, making the stock its 15th largest position. Hhlr Advisors LTD. owned approximately 0.66% of Maze Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of MAZE. Jupiter Topco LLC acquired a new position in shares of Maze Therapeutics in the second quarter valued at approximately $101,764,000. ARCH Venture Management LLC acquired a new stake in shares of Maze Therapeutics during the second quarter worth $122,983,582,000. ADAR1 Capital Management LLC bought a new stake in Maze Therapeutics in the 2nd quarter valued at $10,124,000. Canada Pension Plan Investment Board bought a new stake in Maze Therapeutics in the 2nd quarter valued at $272,000. Finally, Legal & General Group Plc acquired a new position in Maze Therapeutics in the 2nd quarter worth $471,000.

Insider Activity

In other news, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00. Following the completion of the sale, the insider owned 26,250 shares of the company’s stock, valued at approximately $717,675. This represents a 22.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62. Following the sale, the chief marketing officer owned 16,142 shares in the company, valued at $445,680.62. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 108,110 shares of company stock worth $3,057,531. 5.30% of the stock is currently owned by corporate insiders.

Maze Therapeutics Trading Down 2.8%

Shares of MAZE stock opened at $29.58 on Thursday. The stock has a market cap of $1.64 billion, a P/E ratio of -11.74 and a beta of 2.21. Maze Therapeutics, Inc. has a 1 year low of $13.67 and a 1 year high of $53.65. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $28.64 and a 200 day simple moving average of $32.04.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting analysts’ consensus estimates of ($0.76). On average, research analysts predict that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Monday. BTIG Research reissued a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Finally, Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.